Last reviewed · How we verify
Aerosolized 13 cis retinoic acid
Aerosolized 13 cis retinoic acid is a Small molecule drug developed by Kafrelsheikh University. It is currently in Phase 3 development.
At a glance
| Generic name | Aerosolized 13 cis retinoic acid |
|---|---|
| Sponsor | Kafrelsheikh University |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. (PHASE4)
- Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19 (PHASE2)
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) (PHASE3)
- Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus (PHASE2)
- Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications (PHASE1)
- Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. (PHASE1, PHASE2)
- Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword? (PHASE4)
- Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aerosolized 13 cis retinoic acid CI brief — competitive landscape report
- Aerosolized 13 cis retinoic acid updates RSS · CI watch RSS
- Kafrelsheikh University portfolio CI
Frequently asked questions about Aerosolized 13 cis retinoic acid
What is Aerosolized 13 cis retinoic acid?
Aerosolized 13 cis retinoic acid is a Small molecule drug developed by Kafrelsheikh University.
Who makes Aerosolized 13 cis retinoic acid?
Aerosolized 13 cis retinoic acid is developed by Kafrelsheikh University (see full Kafrelsheikh University pipeline at /company/kafrelsheikh-university).
What development phase is Aerosolized 13 cis retinoic acid in?
Aerosolized 13 cis retinoic acid is in Phase 3.